OKYO Pharma Limited (OKYO.L) Publication of a Prospectus

Prospectus Publication Announcement

OKYO Pharma Limited (LSE: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain , announces the publication of its Prospectus in relation to the admission of a further 297,869,806 Ordinary Shares of no par value to listing on the standard segment of the Official List of the FCA and to trading on the Main Market of the London Stock Exchange (together, the “Admission”).


It is expected that Admission will become effective and that dealings will commence at 8.00 a.m. on 7 May 2021.

The Prospectus will be available from the Company’s registered office at Martello Court, Admiral Park, St Peter Port, Guernsey GY1 3HB and online at https://www.okyopharma.com/investors/corporate-documents (subject to applicable securities laws).

An electronic copy of the Prospectus will also be submitted to the National Storage Mechanism and should be available shortly for inspection at http:/data.fca.org/#nsm/nationalstoragemechanism.

OKYO Pharma Limited is a company incorporated in Guernsey with company number 65220. The Ordinary Shares are registered with ISIN GG00BD3FV870, SEDOL code BD3FV87 and TIDM OKYO.

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned
Stockmarket News
Share Talk
Share via
Copy link
Malcare WordPress Security